Interview: Peter Parycek and Noella Edelmann on digital democracy best practice, localism, and e-government

Does democracy have a digital future? At a recent conference at Danube University in Krems, Austria, Sean Kippin asked the co-Chairs of the recent digital democracy and e-government conference (CEDEM) – Peter Parycek and Noella Edelmann – whether politicians were capable of making the necessary transition to digital, what the implications were localism, and which countries were managing the digital transition well

Bis({tris[2-(3,5-di-tert-butyl-2-oxido­benzylideneamino)ethyl]amine}cerium(III)) diethyl ether solvate

The title compound, 2[Ce(C51H75N4O3)]·C4H10O, was obtained in high yield (92%) by reduction of (TRENDSAL)CeIVCl [TRENDSAL is N,N′,N′′-tris­(3,5-di-tert-butyl­salicyl­ide­natoamino)­triethyl­amine] with potassium in THF. The bulky tripodal TRENDSAL ligand effectively encapsulates the central CeIII cation with a Ce—N(imine) distance of 2.860 (2) Å and an average C—N(amine) distance of 2.619 Å within a distorted monocapped octahedral coordination

Current Understanding of Extracellular Vesicle Homing/Tropism

Extracellular vesicles (EVs) are membrane-enclosed packets that are released from cells and subsequently transfer bioactive molecules between cells without directly contacting the target cells. This transfer of molecules can activate consequential processes in recipient cells, including cell differentiation and migration, thus maintaining tissue homeostasis or promoting tissue pathology. A controversial but therapeutically promising aspect of EV biology is their ability to engage defined cells at specific sites. On the one hand, persuasive studies have shown that EVs express surface molecules that ensure EV tissue localization and enable cell-specific interactions, as demonstrated by in vitro and in vivo analyses. This feature of EV biology is being investigated in translational studies to control malignancies, and deliver chemicals and bioactive molecules to combat several diseases. On the other hand, several studies have shown that EVs fail to traffic in hosts in a targeted manner, thus calling the potential roles of EVs as vehicles in drug delivery and cell-free biomodulation into question. In this review, the biology of EV homing/tropism in mammalian hosts is discussed, including the biological characteristics that may explain the controversial aspects of the EV tropism

Corrigendum to ‘‘Alumino-mesostructured Ni catalysts for the direct conversion of ethene to propene” [J. Catal. 305 (2013) 154–168]

Ni/MCM-41 and Ni/AlMCM-41 were synthesized at different Si/Al ratios and tested in the direct conversion of ethene to propene (ETP-reaction). It was intended to evaluate the effect of modifying the catalyst acidity on the ETP-reaction rather than optimizing its performance. All catalysts were characterized by powder XRD, N2-physisorption, 29Si and 27Al MAS NMR, TEM, NH3-TPD, pyridine-DRITFS, H2-TPR, and TPO. Ni/MCM-41 showed low catalytic activity due to its low acidity. Ni/AlMCM-41 catalyst with a Si/Al ratio of 60 had high catalytic activity. Characterization results revealed that the catalyst structure does not have effect on the catalytic activity. Al could be incorporated into the MCM-41 framework up to Si/Al ratio of 16. Two different Ni-composites on the surface of the MCM-41 and AlMCM-41 were observed. Deeper characterization is required to know the Ni state. Important deactivation was observed at 450 °C. The nature of the carbonaceous species and reaction mechanism require deeper characterization

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany

Background: A total of 62/66 (93.9%) residents in a senior citizen home in Bremen, Germany, received the first dose of the Biontech/Pfizer vaccine BNT162b2 on December 27th 2020. After routine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen tests showed positive results on January 5th, all residents and staff were tested by RT-PCR. Results: Nine staff members and 23 residents had a positive result. PCR positive staff members reported mild to severe COVID-19 symptoms, one was hospitalized. None of them had been vaccinated. In contrast, the vaccinated residents reported no or only mild symptoms. Sequencing of the SARS-CoV-2 genomes of infected individuals revealed a monophyletic origin of the outbreak within the PANGO lineage B.1.177.86. Conclusions: In summary, our data show that partial vaccination prevented severe COVID-19 among the residents during this local SARS-CoV-2 outbreak, suggesting a high effectiveness of even a single vaccine dose, but also emphasize that asymptomatic individuals might still be carriers/spreaders

Lipid metabolite biomarkers in cardiovascular disease: Discovery and biomechanism translation from human studies

Lipids represent a valuable target for metabolomic studies since altered lipid metabolism is known to drive the pathological changes in cardiovascular disease (CVD). Metabolomic technologies give us the ability to measure thousands of metabolites providing us with a metabolic fingerprint of individual patients. Metabolomic studies in humans have supported previous findings into the pathomechanisms of CVD, namely atherosclerosis, apoptosis, inflammation, oxidative stress, and insulin resistance. The most widely studied classes of lipid metabolite biomarkers in CVD are phos-pholipids, sphingolipids/ceramides, glycolipids, cholesterol esters, fatty acids, and acylcarnitines. Technological advancements have enabled novel strategies to discover individual biomarkers or panels that may aid in the diagnosis and prognosis of CVD, with sphingolipids/ceramides as the most promising class of biomarkers thus far. In this review, application of metabolomic profiling for biomarker discovery to aid in the diagnosis and prognosis of CVD as well as metabolic abnormalities in CVD will be discussed with particular emphasis on lipid metabolites

Lipid metabolite biomarkers in cardiovascular disease: Discovery and biomechanism translation from human studies

Lipids represent a valuable target for metabolomic studies since altered lipid metabolism is known to drive the pathological changes in cardiovascular disease (CVD). Metabolomic technologies give us the ability to measure thousands of metabolites providing us with a metabolic fingerprint of individual patients. Metabolomic studies in humans have supported previous findings into the pathomechanisms of CVD, namely atherosclerosis, apoptosis, inflammation, oxidative stress, and insulin resistance. The most widely studied classes of lipid metabolite biomarkers in CVD are phos-pholipids, sphingolipids/ceramides, glycolipids, cholesterol esters, fatty acids, and acylcarnitines. Technological advancements have enabled novel strategies to discover individual biomarkers or panels that may aid in the diagnosis and prognosis of CVD, with sphingolipids/ceramides as the most promising class of biomarkers thus far. In this review, application of metabolomic profiling for biomarker discovery to aid in the diagnosis and prognosis of CVD as well as metabolic abnormalities in CVD will be discussed with particular emphasis on lipid metabolites